Member Info for Holden77

Plutus1 . The drop from ~220p to ~60p around 23/10/23 was well overdone - IMO!

If you offset their past Trading Update with Today's Trading Update, CABP should be conservatively priced around 165p today with great potential to grow based on your comments. Very undervalued IMO. DYOR etc.

One more MM tree shake to try and find the stock they need to cover their books?....before hitting 95p by 4.00pm - IMO

Can't be Director trades as they will be in a "close" period and unable to deal ahead of tomorrow's update?

More likely someone buying a large chunk because they see a good return on their investment?

Were FMR LLC part of the IP and are they allowed to sell ?

Obviously, they are otherwise the FCA will be all over this lol!!

It would be interesting to see if there is a restriction on them buying...and effectively averaging out?

If they are allowed to buy more, now would seem th right time/price...unless they know something we dont!

...or, if the restriction is both ways?

06/07/2023 = Admission

04/12/2023 = is the 180 day "lock-up" period for key IPO investors

06/06/2024 = is the 365 days "lock-up" period for Directors/Key Employees

Would be interesting to know how many shares are involved in the above?

I'm assuming none of the above have been able to sell and slip the net!

From the IPO Prsopectus:

Each of the Company, its directors and certain selling shareholders (including the Principal Shareholder (as defined in the Prospectus) and certain of the Company's employees), will be subject to lock-up arrangements restricting the disposal of Ordinary Shares for a period of time following Admission. The Company and certain of the selling shareholders (including the Principal Shareholder) will be subject to 180 day lock-ups from the date of Admission while Directors and certain employees of the Company will be subject to 365 day lock-ups. The lock-up restrictions are subject to certain customary exceptions and may otherwise only be waived with the prior written consent of the Joint Global Co-ordinators.

Looks like the nurds have cottoned onto KETL and are playing silly buggers with their BOTS because they can't find anything better to do with their boring lives!

 HIGHLIGHTS

Engaging with North American cryptocurrency miners

Redesign of Method B for Chinese manufactured mining machines, which opens up a further 75% of total bitcoin mining market for QBT

Method A increases mining performance by nearly 10%

Method B increases mining probability by 2.6 times

I don't think we will ever make any money investing in JIM? It seems to be run solely by and for the purpose of Mr Gr#@t and his family. If JIM is still being advised how to run their operation, within the rules of the FCA, and have lost model B firms because of apparent poor controls then Mr Gr#@t is the one responsible for all this?

You are better off investing elsewhere IMHO.

DYOR

Hi RoxburyHouse,
I'm hoping the same....otherwise, why would anyone transfer shares which are currently "worthless"?
Furthermore, this transaction cannot be a member of the public and has to be by someone in the know? In which case there should be a formal RNS notifying the public what this is in relation to?

If you buy the Nil Paids at 48p, with a view to paying 103p = 151p with the Ords trading at 160p?

If I were on the Executive team at Marks & Spencer I'd be looking to acquire Boohoo or Asos to bring the younger generation on board?
The market caps of both are so low at the moment.
Just my opinion.

OF has not put any news of this 4D Pharma "issue" on their website - now 4 days after the event!
OF were quick to announce that they had loaned $30m to 4D on 29/07/21!

Can anyone confirm if this is still happening and, if so, is anyone attending please?
Surely, a formal RNS has to be made one way or the other?
Thanks.

Published: June 24, 2022 at 6:59 a.m. ET

Merck & Co. on Friday said the European Commission approved the expanded use of its blockbuster cancer drug Keytruda for certain patients with melanoma, the most serious form of skin cancer.

The Kenilworth, N.J., drugmaker said Keytruda is now approved as monotherapy for the treatment of people ages 12 and older with stage IIB or IIC melanoma and who have undergone complete resection.

Merck said the commission also approved expanding the indications for Keytruda in advanced melanoma and stage III melanoma, as adjuvant treatment following complete resection, to include adolescent patients ages 12 and up.

Keytruda, a cancer drug that harnesses a patient's immune system to fight tumors, is approved in dozens of indications around the world. Sales of the drug topped $17 billion last year.

Has it been officially confirmed ASOS will be in the FTSE 250 on Monday, 20/06/22? - I can't see any RNS or news to this effect?

Thanks.

Am I missing something? TheoremRX (according to their website) is a one man (yank)company?

Well done Adamski1.

This is probably what the majority of long term investors are wanting to know so thanks for emailing DDDD.

If anyone from their Investor Relations team (or even senior management) perhaps they will realise our frustrations.

May be the Board or senior management team are not able to buy any further shares at present due to whatever is happening in the background...who knows?

It will be interesting to see how they respond (if they do).

In the meantime, I'm holding on as I really believe that good days are not too far away.

Best wishes everyone.

"this time next year, we will all be_____________"

As we wrap up 2021, we’re encouraged by the increased understanding of the influence of the #microbiome on nearly all systems in the human body, not just the gut. Throughout 2021, more clinical data from @4Dpharmaplc and others in the field, in an ever more diverse set of diseases, further established the role of the microbiome in the future of healthcare. This in turn has driven yet more collaborations and investment in the space.

In 2022, we look forward to the continued advancement of our pipeline of #LiveBiotherapeutics for diseases ranging from #cancer to #asthma to #Parkinsons. Learn more here: https://lnkd.in/d-syMV77

The global asthma treatment market size stood at USD 18.08 billion in 2019 and is projected to reach USD 26.01 billion by 2027, exhibiting a CAGR of 4.5% during the forecast period....

Just saying.
GLA